Accumulating evidence from genetic and biochemical studies implicates dysfunction of the autophagic-lysosomal pathway as a key feature in the pathogenesis of Parkinson's disease (PD). Most studies have focused on accumulation of neurotoxic α-synuclein secondary to defects in autophagy as the cause of neurodegeneration, but abnormalities of the autophagic-lysosomal system likely mediate toxicity through multiple mechanisms. To further explore how endolysosomal dysfunction causes PD-related neurodegeneration, we generated a murine model of Kufor-Rakeb syndrome (KRS), characterized by early-onset Parkinsonism with additional neurological features. KRS is caused by recessive loss-of-function mutations in the ATP13A2 gene encoding the endolysosomal ATPase ATP13A2. We show that loss of ATP13A2 causes a specific protein trafficking defect, and that Atp13a2 null mice develop age-related motor dysfunction that is preceded by neuropathological changes, including gliosis, accumulation of ubiquitinated protein aggregates, lipofuscinosis, and endolysosomal abnormalities. Contrary to predictions from in vitro data, in vivo mouse genetic studies demonstrate that these phenotypes are α-synuclein independent. Our findings indicate that endolysosomal dysfunction and abnormalities of α-synuclein homeostasis are not synonymous, even in the context of an endolysosomal genetic defect linked to Parkinsonism, and highlight the presence of α-synuclein-independent neurotoxicity consequent to endolysosomal dysfunction.
Pubmed ID: 25855184 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets cathepsin B (S-12)
View all literature mentionsThis polyclonal targets VPS4 antibody produced in rabbit
View all literature mentionsThis polyclonal targets Tyrosine Hydroxylase
View all literature mentionsThis polyclonal targets Tyrosine Hydroxylase
View all literature mentionsThis monoclonal targets Human SNCA
View all literature mentionsThis monoclonal targets a-Synuclein
View all literature mentionsThis polyclonal targets SNCA
View all literature mentionsThis polyclonal targets RAB9A
View all literature mentionsThis monoclonal targets p62/SQSTM1
View all literature mentionsThis polyclonal targets p62 Protein (C)
View all literature mentionsThis polyclonal targets Lamp2
View all literature mentionsThis monoclonal targets LAMP-2 (mouse)
View all literature mentionsThis monoclonal targets LAMP-1 (mouse)
View all literature mentionsThis polyclonal targets Iba1
View all literature mentionsThis monoclonal targets Hsc70
View all literature mentionsThis monoclonal targets GM130
View all literature mentionsThis polyclonal targets GFAP
View all literature mentionsThis monoclonal targets GAPDH antibody [6C5]
View all literature mentionsThis monoclonal targets EEA1
View all literature mentionsThis polyclonal targets CTSL2, CTSL1
View all literature mentionsThis polyclonal targets CTSD
View all literature mentionsTransformation software designed to help model and change Oracle account charts. This can be used to reorganize Oracle accounts due to events such as mergers, acquisitions, regulatory requirements and the need for more ranges when the data outgrows the range of the current chart of accounts. FlexField transforms an existing accounting flexfield segment structure, values, code combinations, and CCIDs according to user mappings, and applies the new code combinations and CCIDs. It propagates the change throughout an existing E-Business Suite data, everywhere the accounting flexfield is used. It removes the old code combinations and CCIDs, and aligns the new Chart of Accounts (COA) so that all balances belonging to a single CCID are summarized into a single line.
View all literature mentionsStatistical analysis software that combines scientific graphing, comprehensive curve fitting (nonlinear regression), understandable statistics, and data organization. Designed for biological research applications in pharmacology, physiology, and other biological fields for data analysis, hypothesis testing, and modeling.
View all literature mentionsMus musculus with name B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J from IMSR.
View all literature mentionsThis polyclonal targets Tyrosine Hydroxylase
View all literature mentionsThis polyclonal targets CTSD
View all literature mentionsThis monoclonal targets EEA1
View all literature mentionsThis polyclonal targets cathepsin B (S-12)
View all literature mentionsThis polyclonal targets CTSL2, CTSL1
View all literature mentionsThis polyclonal targets GFAP
View all literature mentionsThis polyclonal targets p62 Protein (C)
View all literature mentionsThis monoclonal targets LAMP-1 (mouse)
View all literature mentionsThis monoclonal targets Hsc70
View all literature mentionsThis polyclonal targets Iba1
View all literature mentionsThis monoclonal targets GM130
View all literature mentionsThis monoclonal targets LAMP-2 (mouse)
View all literature mentionsThis monoclonal targets GAPDH antibody [6C5]
View all literature mentionsThis monoclonal targets Human SNCA
View all literature mentionsThis polyclonal targets RAB9A
View all literature mentionsThis monoclonal targets a-Synuclein
View all literature mentionsThis polyclonal targets Tyrosine Hydroxylase
View all literature mentionsThis monoclonal targets p62/SQSTM1
View all literature mentionsThis polyclonal targets Lamp2
View all literature mentionsMus musculus with name B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J from IMSR.
View all literature mentionsThis polyclonal targets VPS4 antibody produced in rabbit
View all literature mentionsThis polyclonal targets Tyrosine Hydroxylase
View all literature mentionsThis polyclonal targets SNCA
View all literature mentions